Israel Englander Metacrine, Inc. Transaction History

Millennium Management LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$0.35 - $0.46 $33,961 - $44,635	97,033 New	97,033 $43,000
Q1 2022 May 16, 2022	SELL	$0.43 - $0.7 $30,537 - $49,711	-71,017 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$0.64 - $3.83 $75,859 - $453,973	-118,531 Reduced 62.53%	71,017 $48,000
Q3 2021 Nov 15, 2021	SELL	$2.61 - $3.84 $187,585 - $275,988	-71,872 Reduced 27.49%	189,548 $650,000
Q2 2021 Aug 16, 2021	SELL	$3.37 - $5.73 $86,025 - $146,269	-25,527 Reduced 8.9%	261,420 $993,000
Q1 2021 May 17, 2021	SELL	$6.2 - $11.0 $256,301 - $454,729	-41,339 Reduced 12.59%	286,947 $1.78 Million
Q4 2020 Feb 16, 2021	BUY	$7.75 - $11.42 $1.96 Million - $2.89 Million	253,123 Added 336.77%	328,286 $2.58 Million
Q3 2020 Nov 16, 2020	BUY	$9.38 - $11.76 $705,028 - $883,916	75,163 New	75,163 $763,000

Ticker MTCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,569,500
Description
Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.